Strategic partnerships PHAR engages with big pharma and associations on research and health economics projects, highlighting opportunities to collaborate with major companies like Bristol Myers Squibb, PhRMA, and Genentech for payer analytics, treatment pattern studies, and cost-effectiveness analyses.

Health economics focus A strong emphasis on health economics and outcomes research suggests a sales angle around economic modeling, real-world evidence generation, and value dossiers for new and existing pharmaceuticals.

Clinical analytics Experience with claims-based algorithms and resource utilization studies indicates potential to offer advanced analytics services for patient identification, treatment pathways, and cost-of-illness assessments.

Lifecycle collaboration PHAR’s work spans research, development support, and marketing strategy, enabling cross-functional engagements from early development to post-market evidence, ideal for selling integrated consulting packages.

Scale and reach With mid-size operations and partnerships across top pharma players, PHAR is positioned to scale through expanded projects, leveraging existing collaborations to enter adjacent therapeutic areas and geographies.